Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case

United Therapeutics Corporation (NASDAQ:UTHR) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 2, Jefferies reiterated its “Buy” rating and a price target of $564 for United Therapeutics Corporation (NASDAQ:UTHR). This decision comes amid ongoing legal proceedings related to a patent dispute. The patent dispute involves interpretations of a recent Bayer case. Judge Andrews is currently reviewing letters from both parties about whether certain dependent claims (claims 5, 6, 9 & 17) have sufficient “patentable weight” for the case’s anticipation/obviousness analysis.

If only these dependent claims are found valid and infringed, United Therapeutics could block competitor Yutrepia or seek damages, but only for products or uses that meet the narrower requirements of those claims. The next step is a court order on the “patentable weight” issue for dependent claims; both parties can appeal the decision.

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company. It develops and commercializes therapies for pulmonary arterial hypertension (PAH) and other chronic and life-threatening conditions. Its key products include Remodulin, Tyvaso, Orenitram, and Unituxin.

While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Performing NASDAQ Stocks According to Hedge Funds and 10 High-Growth Semiconductor Stocks That Are Profitable in 2025.

Disclosure: None. This article is originally published at Insider Monkey.